| HOME >> MEDICINE >> TECHNOLOGY |
8,5367,44731,71527,929Product Gross Profit
4,7304,41518,63616,027Product Gross Margin
36%37%37%36% Research and development
2,0681,0206,1985,829 Selling, general and administrative
6,1944,64927,66229,520Total operating expenses
16,79813,11665,57563,278Operating income (loss) from continuing operations
(3,201)240(13,502)(14,459)Other Income and Expense:
Interest and other expense, net
(1,301)(1,125)(7,481)(10,105) Loss on debt extinguishment
----(3,384)-- Gain on debt extinguishment upon conversion
--3175988,946 Gain on amendment of 2008 Notes
------3,977 Gain (loss) on net change in fair value of derivative assets and liabilities
872199(145)5,277Total other income (expense), net
(429)(609)(10,412)8,095Loss from continuing operations before income taxes
(3,630)(369)(23,914)(6,364)Income tax benefit
1,820--9,748--Net loss from continuing operations
(1,810)(369)(14,166)(6,364)Discontinued Operations:
Net income (loss) from discontinued operations, net of income taxes
(1,490)(11,438)8,816(49,876)Less: Loss attributed to noncontrolling interests in consolidated entities – discontinued operations
--8,84925,28334,349Net income (loss) attributed to Verenium
$
(3,300)$
(2,958)$
9,933$
(21,891)Basic and diluted net income (loss) per share:
Continuing Operations
$
(0.14)$
(0.03)$
(1.15)$
(0.75)Discontinued Operations
$
(0.12)$
(1.00)$
.72$
(5.89)Net income (loss) attributed to Verenium
$
(0.26)$
(0.26)$
.62$
(2.58)Shares used in computing basic and diluted net income (loss) per share
12,59111,49312,3218,470Verenium CorporationCondensed Consolidated Balance Sheet Data(unaudited, in thousands)December 31,December 31,20102009Cash and cash equivalents
$
87,929$'/>"/>
| SOURCE Verenium Corporation Copyright©2010 PR Newswire. All rights reserved |